Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver
A Phase II Study Of Adjuvant Intravenous Irinotecan Following Resection With Or Without Radiofrequency Ablation (RFA), Of Hepatic Metastases From Colorectal Carcinoma
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug after surgery and radiofrequency ablation may kill any remaining tumor cells.
PURPOSE: Phase II trial to determine the effectiveness of surgery with or without radiofrequency ablation followed by irinotecan in treating patients who have colorectal cancer that is metastatic to the liver.
調査の概要
詳細な説明
OBJECTIVES:
- Determine the disease-free survival in patients with hepatic metastases from primary colorectal carcinoma treated with surgical resection with or without radiofrequency ablation followed by irinotecan.
- Determine the overall survival in patients treated with this regimen.
- Determine the treatment-related toxicity of this regimen in these patients.
- Correlate the measurement of molecular markers with clinical outcome in patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified according to treatment with radiofrequency ablation in addition to resection (yes vs no).
Patients undergo surgical resection with or without radiofrequency ablation. Beginning 4-8 weeks after surgery, patients receive irinotecan IV over 90 minutes on day 1. Chemotherapy repeats every 3 weeks for a total of 6 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed at 4 weeks, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.
研究の種類
段階
- フェーズ2
連絡先と場所
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
- Histologically confirmed primary colorectal adenocarcinoma
Hepatic metastases that are considered completely resectable
- No more than 4 metastases by dual phase CT scan OR
Hepatic metastases that are not completely resectable but are amenable to complete destruction with resection and radiofrequency ablation
- More than 4 metastases allowed if all disease can be resected or destroyed in situ with radiofrequency ablation
- No extrahepatic disease in any location
- No recurrent or second primary colorectal cancer by colonoscopy within the past year
- Received prior adjuvant chemotherapy with a fluorouracil-based regimen with the last dose at least 1 month prior to surgery
- No prior radiofrequency ablation with residual viable intrahepatic disease by CT scan
- No plans to be treated with radiofrequency ablation alone without surgical resection
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST and ALT no greater than 5 times ULN
- No Gilbert's disease or other known defect in hepatic conjugation or glucuronidation
Renal:
- Creatinine no greater than 1.5 times ULN
Cardiovascular:
- No myocardial infarction within the past 6 months
- No congestive heart failure requiring therapy
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for 30 days after study
- No other malignancy within the past 5 years except inactive non-melanoma skin cancer or carcinoma in situ of the cervix
- No active serious infection
- No other serious underlying medical condition or severe concurrent disease that would preclude study participation
- No dementia, significantly altered mental status, or psychiatric illness that would preclude study participation
- No known hypersensitivity to irinotecan
- No known infection with HIV or AIDS
- No uncontrolled diabetes mellitus
- No history of seizures
- No drug or alcohol abuse within the past year
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- See Disease Characteristics
- No prior irinotecan
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy to more than 30% of bone marrow
- No prior radiotherapy to the liver
- At least 3 months since prior radiotherapy to the pelvis or other areas
Surgery:
- See Disease Characteristics
- No prior resection of hepatic metastases (wedge biopsy allowed)
Other:
- No concurrent phenytoin, phenobarbital, or other antiepileptic medication
- No concurrent enrollment in other investigational drug trials
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
協力者と研究者
スポンサー
捜査官
- スタディチェア:Kevin G. Billingsley, MD、University of Washington
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
大腸がんの臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ
イリノテカン塩酸塩の臨床試験
-
University of CologneServier募集
-
Massachusetts General HospitalStand Up To Cancer募集